Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)

NCT01554176 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

129

Enrollment

INDUSTRY

Sponsor class

Stopped Low Enrollment

Conditions

Major Depressive Disorder, Recurrent

Interventions

DRUG: Filorexant
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC